SEC Filing Summary: The Cooper Companies, Inc. (10-K)
Business Context and Reporting Period
Company: The Cooper Companies, Inc. (TCC)
Reporting Period: Fiscal year ended October 31, 1993
Business Overview: TCC operates through four primary segments: Hospital Group of America (HGA), providing psychiatric and substance abuse treatment; CooperVision, manufacturing contact lenses; CooperSurgical, producing diagnostic and surgical instruments; and CooperVision Pharmaceuticals (CVP), developing ophthalmic drugs. The company has pursued a diversification strategy since 1989, moving beyond its original contact lens focus.
Key Financial Metrics
| Metric | 1993 | 1992 | 1991 |
|---|---|---|---|
| Net Operating Revenue | $92,652,000 | $63,279,000 | $35,524,000 |
| Net Loss | ($46,805,000) | ($24,818,000) | ($19,375,000) |
| Loss per Common Share | ($1.55) | ($0.96) | ($0.84) |
| Cash and Cash Equivalents | $10,113,000 | $38,078,000 | $76,652,000 |
| Total Assets | $109,524,000 | $173,007,000 | $187,633,000 |
| Total Liabilities | $109,072,000 | $126,710,000 | $115,931,000 |
| Stockholders' Equity | $452,000 | $46,297,000 | $71,702,000 |
| Long-Term Debt | $48,077,000 | $58,591,000 | $48,657,000 |
Note: The filing does not provide a specific "Operating Margin" percentage, but HGA operating profit was 5.6% of net service revenue in 1993, down from 10.6% in 1992. Consolidated gross margin for products was 63% in 1993.
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenue increased 46% to $92.7 million, driven primarily by the acquisition of Hospital Group of America (HGA) in May 1992 and CoastVision in April 1993.
- Significant Losses: Net loss more than doubled to $46.8 million. This was driven by a $13.7 million charge for discontinued operations (breast implant litigation accrual), $6.4 million in settlement of disputes, and $2.1 million in debt restructuring costs.
- Liquidity Deterioration: Cash and cash equivalents declined by $27.9 million (73%) due to legal settlements, acquisitions, and operating losses. Stockholders' equity collapsed from $46.3 million to $0.5 million.
- Debt Restructuring: The company completed an exchange offer in January 1994 (subsequent to period end) to restructure $30 million of debentures, issuing new notes and paying cash to avoid default.
Guidance, Outlook, Risks, and Contingencies
Going Concern Warning: The independent auditors (KPMG Peat Marwick) issued a report stating that the company's significant losses, negative cash flows, and contingent liabilities raise substantial doubt about its ability to continue as a going concern. The financial statements do not include adjustments that might result from the outcome of these uncertainties.
Legal and Regulatory Risks:
- Criminal Conviction: The company was found guilty on six counts of mail fraud and one count of wire fraud related to a "trading scheme" by former Co-Chairman Gary Singer. Sentencing was scheduled for March 1994, with potential penalties including fines and restitution.
- SEC Action: The SEC filed a civil complaint alleging securities law violations. The company is in settlement negotiations, but penalties could exacerbate liquidity issues.
- Breast Implant Litigation: The company is a defendant in over 2,600 lawsuits. A settlement with Medical Engineering Corporation (MEC) in September 1993 limited liability, requiring the company to pay between $12 million and $30 million over ten years based on future net income.
- Healthcare Reform: Pending national healthcare reform proposals could materially adversely affect revenues and cash flows.
Outlook: Management anticipates net cash outflows in fiscal 1994 due to legal costs, R&D, and potential penalties. The company may need to raise funds through borrowings or asset sales.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to secure additional financing or refinance debt to meet obligations given the "substantial doubt" auditor warning.
- Legal Penalties: Monitor the outcome of the criminal sentencing (March 1994) and the SEC settlement negotiations for potential monetary penalties.
- Breast Implant Liability: Confirm the final payment schedule to MEC and the impact of the contingent payments based on future profitability.
- Debt Covenants: Review the terms of the new 10% Senior Subordinated Secured Notes issued in January 1994 and the waiver of defaults obtained.
- HGA Operations: Investigate the billing irregularities reported at Hampton Hospital and the status of the management agreement with Nu-Med subsidiaries.